Enfusion, Inc. (NYSE:ENFN) CFO Sells $41,877.42 in Stock

Enfusion, Inc. (NYSE:ENFN) CFO Bradley Herring sold 4,134 shares of the business’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $10.13, for a total value of $41,877.42. Following the sale, the chief financial officer now directly owns 266,369 shares of the company’s stock, valued at $2,698,317.97. This represents a 1.53 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Bradley Herring also recently made the following trade(s):

• On Friday, December 20th, Bradley Herring sold 24,443 shares of Enfusion stock. The shares were sold at an average price of $10.61, for a total value of $259,340.23.

Enfusion Stock Down 3.1 %

NYSE ENFN opened at $9.97 on Friday. The firm has a market cap of $1.28 billion, a price-to-earnings ratio of 249.31, a price-to-earnings-growth ratio of 3.98 and a beta of 0.95. Enfusion, Inc. has a twelve month low of $7.52 and a twelve month high of $11.38. The business has a 50-day moving average price of $10.11 and a 200-day moving average price of $9.19.

Wall Street Analyst Weigh In

Several research firms have issued reports on ENFN. Piper Sandler boosted their price target on Enfusion from $10.00 to $11.50 and gave the company a “neutral” rating in a report on Monday, December 23rd. Stifel Nicolaus upped their price objective on Enfusion from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, December 18th. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $10.25.

Institutional Investors Weigh In On Enfusion

A number of hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC lifted its position in shares of Enfusion by 7.3% in the third quarter. Geode Capital Management LLC now owns 1,029,366 shares of the company’s stock worth $9,770,000 after buying an additional 70,367 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Enfusion by 6.7% in the third quarter. Wellington Management Group LLP now owns 976,296 shares of the company’s stock worth $9,265,000 after buying an additional 61,032 shares in the last quarter. State Street Corp lifted its position in shares of Enfusion by 2.3% in the third quarter. State Street Corp now owns 952,895 shares of the company’s stock worth $9,043,000 after buying an additional 21,729 shares in the last quarter. Impax Asset Management Group plc lifted its position in shares of Enfusion by 25.4% in the third quarter. Impax Asset Management Group plc now owns 676,948 shares of the company’s stock worth $6,424,000 after buying an additional 136,948 shares in the last quarter. Finally, Scalar Gauge Management LLC lifted its position in shares of Enfusion by 21.8% in the second quarter. Scalar Gauge Management LLC now owns 613,513 shares of the company’s stock worth $5,227,000 after buying an additional 110,000 shares in the last quarter. 81.05% of the stock is currently owned by hedge funds and other institutional investors.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.